Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
公共新抗原疫苗2
- Development stage
- Preclinical
- Lead developer
- NeoCura
- Modality
- Vaccines & Immunotherapeutics
01
Overview
公共新抗原疫苗2 (Public Neoantigen Vaccine 2) is an early-stage therapeutic cancer vaccine developed by Neocura (北京新合睿恩生物医疗科技) for the treatment of solid tumors. The vaccine is designed to target shared (public) tumor neoantigens, which are immunogenic mutations commonly shared among different cancer patients. By delivering these public neoantigens, the vaccine aims to stimulate a robust, tumor-specific T-cell immune response to eliminate cancer cells. It is currently in the IND-enabling/clinical application stage.
- Other names
- Public Neoantigen Vaccine 2Shared Neoantigen Vaccine 2
02
Targets
γδ TCR (T-cell receptor)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on 公共新抗原疫苗2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 公共新抗原疫苗2.